Rana R. McKay, MD, University of California San Diego Medical Center

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 29th 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Ongoing Clinical Trials in the Metastatic CRPC Setting

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 29th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Potential for CDK4/6 Inhibitors in Metastatic CRPC

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 22nd 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

Novel Therapeutic Targets in Metastatic CRPC

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

August 22nd 2023

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Systemic Treatment Armamentarium in Metastatic HSPC

Rana R. McKay, MD, University of California San Diego Medical Center;Arash Rezazadeh Kalebasty, MD ;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD

June 26th 2023

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

Rana R. McKay, MD, University of California San Diego Medical Center;Sumit K. Subudhi, MD, PhD;Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College;Ulka Vaishampayan, MD;Arash Rezazadeh Kalebasty, MD

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Future of Treating mRCC

Daniel J. George, MD, Duke Cancer Center;Neeraj Agarwal, MD, Huntsman Cancer Institute;Rana R. McKay, MD, University of California San Diego Medical Center;Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

Rana R. McKay, MD, University of California San Diego Medical Center

Articles

Latest Updated Articles

Latest Conference Coverage